Zyprexa On More Level Playing Field After Diabetes Class Label Changes, Lilly Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Physicians will be more inclined to prescribe atypical antipsychotics based on efficacy rather than side effects now that "virtually" all NDA holders have revised labeling, Lilly says. Pfizer (Geodon) remains the lone holdout.
You may also be interested in...
Geodon Labeling Changes Still Under Discussion, Pfizer Says
Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report
Geodon Labeling Changes Still Under Discussion, Pfizer Says
Pfizer is continuing to discuss new safety labeling for the antipsychotic Geodon (ziprasidone) with FDA, the company said in its April 20 earnings report
Bristol Adds Diabetes Class Warning To Abilify Labeling; “Paucity” Of Reports Cited For Antipsychotic
Bristol and Otsuka had been seeking to persuade FDA that the atypical antipsychotic should be exempt from a class-wide hyperglycemia warning. Bristol will continue discussions with the agency as new data become available.